Project Details
Description
We aim to develop an Epstein-Barr virus (EBV) inhibitor for therapeutic intervention of EBV-associated malignancies. Basic CMC of the candidate drugs will be defined, formulation of drug delivery will be determined. The minimum (ED) and median (ED50) effective doses for tumor size reduction in response to our candidate drugs will be identified, one lead compound will be chosen. MoA, PK, TOX, and biodistribution of the lead compound will be determined.
| Status | Active |
|---|---|
| Effective start/end date | 2/10/24 → 31/12/25 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.